Limited advances in therapy of glioblastoma trigger re-consideration of research policy

Research output: Contribution to journalArticlepeer-review


Glioblastoma (GB - WHO grade IV) is the most frequent and lethal primary brain tumour with median overall survival of 7-15 months after diagnosis. As in other cancer research areas, an overwhelming amount of pre-clinical research acquisitions in the GB field have not been translated to patients' benefit, potentially due to inappropriate treatment schedules and/or trial designs in the clinical setting. The recent failure of promising anti-VEGF bevacizumab to improve GB patients' overall survival recapitulates this sense of frustration. The following measures are proposed:. change Phase II design. Bevacizumab and other drugs may have failed in Phase III just because of an inappropriate clinical treatment schedule adopted. Multiple-step Phase II clinical trials allowing more thorough definition of treatment protocols to be extensively studied in Phase III should be monitor standards of care by documenting survival rates of GB patients in European Cancer Units, in order to homogenize GB treatment quality to the highest possible level all over introduce the therapeutic impact factor (TIF) and therapeutic (t) index bibliometric parameters, in order to orientate pre-clinical research toward more therapy-focussed activities.

Original languageEnglish
Pages (from-to)257-261
Number of pages5
JournalCritical Reviews in Oncology/Hematology
Issue number2
Publication statusPublished - Nov 1 2015


  • Bevacizumab
  • Bibliometrics
  • Glioma
  • Treatment protocol
  • Treatment quality

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology


Dive into the research topics of 'Limited advances in therapy of glioblastoma trigger re-consideration of research policy'. Together they form a unique fingerprint.

Cite this